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Summary The prevalence, incidence, risk factors and prognosis of silent myocardial infarc-
tion are less well known than those of silent myocardial ischaemia. The aims of this article are to
evaluate the prevalence and incidence of silent myocardial infarction in subjects with or without
a history of cardiovascular disease and in diabetic patients, and to identify potential risk factors
and estimate prognosis through a review of the literature. A Medline search identiﬁed studies
that provided data on the prevalence, incidence, potential risk factors and/or prognosis of silent
myocardial infarction, among cohorts from the general population and large clinical studies of
at-risk patients (with hypertension or a history of cardiovascular disease or diabetes). The search
identiﬁed 15 studies in subjects from the general population, ﬁve in hypertensive patients, six
in patients with a history of cardiovascular disease, and 10 in diabetic patients. The prevalence
and incidence of silent myocardial infarction appear highly variable depending on the popula-
tion studied, the patients’ ages, and the method used to detect silent myocardial infarction. In
the general population, the prevalence of silent myocardial infarction increased markedly with
increasing age (up to > 5% in elderly subjects). Hypertension causes only a moderate increase
in prevalence, whereas underlying cardiovascular diseases and diabetes are associated with
marked increases in prevalence. The incidence of silent myocardial infarction changes in the
same way. The main predictive factors of silent myocardial infarction are hypertension, history
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of cardiovascular diseases and diabetes duration. Silent myocardial infarction is associated
with as poor a prognosis as clinical myocardial infarction. The frequency of silent myocardial
infarction and the poor prognosis in at-risk patients amply justify its systematic early detection
and active management.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé Comparativement à l’ischémie myocardique silencieuse, la prévalence et l’incidence
de l’infarctus du myocarde silencieux (IDMs), ses facteurs de risque et son pronostic sont mal
connus. Évaluer la prévalence et l’incidence de l’IDMs chez des sujets avec/sans antécédents
cardiovasculaires et chez des diabétiques, identiﬁer ses facteurs de risque et estimer son
pronostic, à partir des données de la littérature. La recherche a été effectuée dans Medline pour
identiﬁer, parmi les cohortes de sujets de population générale et les grandes études de patients
à risque (hypertension, maladies cardio-vasculaires, diabète), celles évaluant la prévalence et
l’incidence de l’IDMs, ses facteurs de risque et son pronostic. La recherche a identiﬁé 15 études
en population générale, cinq chez des patients hypertendus, six chez des patients avec antécé-
dents cardiovasculaires et dix chez des patients diabétiques. La prévalence et l’incidence de
l’IDMs apparaissent très variables selon la population étudiée, l’âge des patients et la méthode
de détection. En population générale, la prévalence de l’IDMs augmente nettement avec l’âge
(jusqu’à > 5% chez les sujets âgés). L’hypertension augmente modérément la prévalence, tandis
que les maladies cardiovasculaires sous-jacentes et le diabète induisent une nette augmentation
de la prévalence de l’IDMs. L’incidence de l’IDMs varie parallèlement. Les principaux facteurs
pronostiques sont l’hypertension, les maladies cardiovasculaires et la durée du diabète. Enﬁn,
le pronostic de l’IDMs est aussi péjoratif que celui de l’IDMs clinique. La fréquence et le mauvais
pronostic de l’IDMs chez les patients à risque justiﬁent son diagnostic systématique précoce et
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Background
A substantial number of myocardial infarctions (MIs) are
asymptomatic or associated with minor and atypical
symptoms, and are found accidentally during routine elec-
trocardiogram (ECG) examinations that reveal the existence
of abnormal Q waves. The possible causes of blunted MI per-
ception in some patients remain ill deﬁned, but there may
be some impairment of the stimulation of cardiac recep-
tors, impulse initiation, or conduction, or of cerebral pain
perception [1]. Symptoms are often atypical or even absent,
especially in diabetic patients — a population particularly at
risk for coronary artery disease (CAD) [2].
Compared with the frequency of silent myocardial
ischaemia, which is deﬁned as evidence of myocardial
ischaemia in the absence of signs of angina [3—5], the fre-
quency of silent MI, which is unequivocal objective signs of
infarction accompanied by unrecognized minimal, atypical
symptoms or no symptoms at all, is less well known. Data
may be collected, however, from studies that followed sub-
jects from the general population or subjects at risk for
CAD, such as those with hypertension or a history of car-
diovascular disease, and also from large clinical studies that
have been conducted for the evaluation of antidiabetic or
hypolipidaemic therapies.
The aim of the present study was to retrieve information
on the prevalence, incidence, and predictive/prognostic
factors of silent MI, and to assess the inﬂuence of poten-
tial factors such as age, hypertension, other cardiovascular
disorders, and diabetes that may promote the occurrence of
silent MI.
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cs droits réservés.
ethods
rticles meeting the study objectives were identiﬁed by
earching the MEDLINE database. Only relatively recent
tudies (from 1980 onwards) were retained for analysis,
iven that the detection and management of infarction may
ave changed considerably over time. Furthermore, stud-
es essentially focused on the treatment of coronary heart
isease were excluded.
A general search was ﬁrst performed using the fol-
owing keywords: ‘‘silent myocardial infarction’’ and
‘unrecognized myocardial infarction’’. Furthermore, a
anual search was conducted from the bibliographic ref-
rences quoted in the selected publications, and also from
he ‘‘related citations’’ in PubMed. The information gath-
red was then analysed to estimate the prevalence of silent
I in the populations considered and the incidence over the
ollow-up period in each study.
Hereafter, the prevalence of silent MI is expressed as
he proportion of patients with silent MI detected by the
resence of a Q wave on the ECG or of abnormalities at
tress echocardiography, delayed gadolinium-enhanced car-
iac magnetic resonance imaging (DGE-MRI), or scintigraphy
n the absence of a previous history or obvious clinical symp-
oms of MI. The prevalence of silent MI is also expressed as
he proportion relative to all clinical MIs or all non-fatal MIs.
he incidence of silent MI is either reported as the number of
ncident cases per 1000 patient-years, or estimated from the
umulative number of cases observed referred to the dura-
ion of the follow-up period and expressed as the number of
ases per 1000 patient-years.
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esults of the bibliographic search
he search in MEDLINE allowed the initial identiﬁcation and
election of:
23 general publications on silent MI;
134 articles on studies conducted in patients with hyper-
tension;
nine articles on studies conducted in patients with CAD
(ﬁve studies), thrombosis (two studies), or cardiac dyski-
nesia (two studies);
73 articles on clinical studies conducted in diabetic
patients;
eight articles in patients with diabetic neuropathy;
24 articles on clinical studies conducted in patients with
dyslipidaemia;
14 articles on studies conducted in patients with
nephropathy.
In addition to these 285 publications, 16 articles were
dentiﬁed by the manual search. Analysis of all these articles
nally allowed the selection of 36 articles reporting data on
ilent MI: 15 in healthy subjects from the general population,
ve in hypertensive patients, six in patients with a history
f cardiovascular disease, and 10 in diabetic patients.
ethods of silent MI diagnosis
n most studies, diagnosis of silent MI was based on the exis-
ence of a Q wave on ECG, and in some cases on R-wave
eduction or abnormalities of the ST segment and/or T wave
s coded according to the Minnesota classiﬁcation [6,7]. In
ome studies, silent MI was detected by stress echocardiog-
aphy (one study), dipyridamole/exercise stress scintigraphy
two studies) or delayed DGE-MRI (three studies) which in
ddition detected non-Q-wave silent MIs.
The choice of the detection method may have had an
mpact on silent MI diagnosis, as there may be a relationship
etween the knowledge of a patient’s medical history at the
ime of examination, the choice of the detection method,
nd the accuracy of the diagnosis. An ECG is indeed the pre-
erred detection method for patients with no obvious sign
f MI, but may show low sensitivity, whereas more sophis-
icated methods used in patients with a stronger suspicion
f MI may show greater sensitivity (e.g. DGE-MRI), possibly
t the cost of lower selectivity (e.g. stress methods may
rroneously detect reversible ischaemia).
esults
revalence of silent MI in the general
opulation
ata on the prevalence of silent MI were obtained from
0 studies conducted in Europe, North America and India
n healthy subjects from the general population, either
dults (eight studies) [8—15] or elderly subjects (two stud-
es) [16,17] (Table 1). In all these studies, silent MI was
etected by ECG (Q wave and/or ST-T abnormalities in two
tudies) (Table 1). The patient populations comprised only
ow proportions of diabetic patients (0—7.6% of subjects
ged < 65 years; 9.8—12.4% of those aged > 65 years).
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These data suggest a strong relationship between sub-
ects’ age and prevalence of silent MI. The prevalence
f silent MI was lowest (0.3—0.5%) in the studies that
ncluded young subjects (Rochester cohort and Reykjavik
ale cohort) [10,14] and highest (3.4—6.4%) in those that
ncluded older subjects (Rotterdam, Olmsted, Cardiovascu-
ar Health Study [CHS], and Bronx Aging Study [AS] cohorts)
8,9,16,17]. The prevalence of silent MI was also high among
he young subjects included in the Northern Sweden Moni-
oring of Trends and Determinants in Cardiovascular Disease
MONICA) cohort (4.8%) [11]. This is probably because this
articular ethnic group is more likely to develop CAD (8.6% of
ubjects had impaired glucose tolerance). The direct rela-
ionship between age and the prevalence of silent MI was
ell assessed in the two Reykjavik cohorts: in middle age
∼ 60 years), the prevalence of silent MI was estimated at
—1.5% in men and women, but this was much higher (> 5%)
n men aged > 75 years [13,14]. Geographic location does not
eem to exert a notable inﬂuence. In the studies in rela-
ively young people, silent MIs accounted for 42—64% of all
Is [8—15], whereas this proportion was lower (22—35%) in
lder subjects (CHS and Bronx AS cohorts) [16,17] (Table 1).
revalence of silent MI in high-risk
opulations: patients with hypertension or a
istory of CAD
he two studies [18,19] of hypertensive subjects that
rovided prevalence data reported somewhat conﬂicting
esults. In the Medical Research Council (MRC) trial, which
ncluded mildly hypertensive patients [18], hypertension did
ot seem to be associated with increased prevalence of
ilent MI, whereas in the International Prospective Primary
revention Study in Hypertension (IPPPSH)-Italia study [19],
he prevalence of silent MI appeared moderately elevated
ompared with that in normotensive subjects of similar age
except for the MONICA study [11] and the Olmsted study
9]; see above) from the general population (Table 2).
The four studies in patients with a history of cardiovas-
ular disease [20—23] showed a notably higher prevalence
f silent MI (Table 2). In patients with a history of cardio-
ascular disease, including those with a clinical suspicion
f CAD or with non-cardiac vascular surgery, the observed
revalence of silent MI reached 23% in both a European and
North American study where silent MI was detected by
tress echocardiography or DGE-MRI [21,23]. The prevalence
f silent MI was similar (27%) in a study of patients with
uspected CAD in whom silent MI was detected by DGE-MRI
compared with only 8.1% by ECG) [20]. It was found to be
ower, however, in a study that included a high proportion of
iabetic patients in whom silent MI was detected by exer-
ise stress scintigraphy [22]. In two studies where both types
f data were available, the proportion of silent MI patients
as notably higher amongst diabetic patients compared with
heir non-diabetic counterparts [21,22].revalence of silent MI in diabetic patients
ata on the prevalence of silent MI in diabetic patients were
etrieved from four articles (Table 3) [24—27]. One of them
oncerned the Australian Fremantle cohort, which included
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Table 1 Prevalence of silent MI in the general population.
Cohort name and/or year Region n Sex Mean or
range age
(years)
Method of
diagnosis
Prevalence
(%)
Proportion of
all MIs (%)
Bronx AS 1990 [17] USA 390 M/F 79 ECG Q wave 6.4 35
1992 [15] India 5621 M/F 25—64 ECG Q wave 1.4 —
Reykjavik 1995 [14] Europe 9141 M 33—60 at
entry
ECG 0.5 at age
50 to > 5 at
age 75
54
Reykjavik 1998 [13] Europe 9773 F 32—59 at
entry
ECG < 1 at age
60 to 1.9%
at age 75
42
BRHS 2000 [12] Europe 7735 M 50 ECG 1.7 46
CHS 2000 [16] USA 5888 M/F 72 ECG Q
wavea
3.4 22
MONICA 2003 [11] Europe 771 M/F 45 ECG Q wave 4.8 64
Olmsted 2005 [9] USA 2042 M/F 62 ECG Q
wavea
3.9 44
Rochester 2005 [10] USA 603 M/F 58 ECG 0.3 —
Rotterdam 2008 [8] Europe 6347 M/F 69 ECG Q wave 5.4 45
AS: Aging Study; BRHS: British Regional Heart Study; CHS: Cardiovascular Health Study; ECG: electrocardiogram; F: female; M: male;
MI: myocardial infarction; MONICA: monitoring of trends and determinants in cardiovascular disease.
a And ST-T abnormalities.
Table 2 Prevalence of silent MI in at-risk subjects.
Cohort name and/or year Region n Sex Mean or
range age
(years)
Method of
diagnosis
Prevalence
(%)
Patients with arterial hypertension
MRC trial 1988 [18] Europe 17 354 M/F 35—64 ECG Q wave M/F
1.3/1.5
IPPPSH 1988 [19] Europe 746 M/F 40—64 ECG Q wave M/F
2.4/3.3
Patients with a history of cardiovascular disease
2006 [22] USA 579 M/F — Exercise
stress
scintigra-
phy
7.1
(diabetics
18.4)
2006 [23] USA 195 M/Fa 59 DGE-MRI 22.6
2007 [21] Europe 1092 M/Fb 64 Stress
echocardio-
graphy
23.4
(diabetics
34)
2009 [20] USA 185 M/Fa 60 ECG Q
wave/DGE-
MRI
ECG/MRI
8.1/27.0
DGE-MRI: delayed-gadolinium enhanced-magnetic resonance imaging; ECG: electrocardiogram; F: female; IPPPSH: International
Prospective Primary Prevention Study in Hypertension; M: male; MI: myocardial infarction; MRC: medical research council.
a Subjects with suspected or known CAD.
b Patients undergoing non-cardiac vascular surgery.
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Table 3 Prevalence of silent MI in diabetic patients.
Cohort name and/or year Region Number of
subjects
Sex Mean or
range age
(years)
Method of
diagnosis
Prevalence
(%)
Proportion
of all MIs
(%)
1986 [27] USA 73a M/F 50 ECG 10 70
1990 [26] USA 30b M/F 66 DTS 37 —
Fremantle 2004 [24] Australia 1269c M/F 64 ECG Q wave 3.9 44
2008 [25] USA 107d M/F 61 DGE-MRI 28 29
DGE-MRI: delayed gadolinium enhanced-magnetic resonance imaging; DTS: dipyridamole thallium scintigraphy; ECG: electrocardiogram;
F: female; M: male; MI: myocardial infarction.
a Subjects with type 1 or 2 diabetes and peripheral or cardiac neuropathy.
b Subjects with type 1 or 2 diabetes without evidence of CAD, but with peripheral artery disease.
c Subjects with recent type 2 diabetes, mainly (75%) without history of CAD.
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Ad Subjects with suspicion of CAD.
269 patients with type 2 diabetes of median 4-year duration
24]. The three other studies were smaller series of 30—107
iabetic patients that were carried out in North America. In
ddition to diabetes, patients included in two studies had
cardiovascular disease (suspicion of CAD based on recent
uggestive symptoms [25] or peripheral artery disease [26])
r, in another study, peripheral or cardiac neuropathy char-
cterized by the Valsalva test [27]. Some patients (25%) of
he Fremantle cohort also had CAD [24].
Prevalence data from these four studies in diabetic
atients revealed various proportions of silent MI patients,
epending on the characteristics of the patients included
nd the detection method used. In diabetic patients from
he general population (Fremantle cohort), the prevalence
f silent MI evaluated by ECG was about 4% [24]. The
revalence of silent MI increased to 10% when diabetes
as associated with peripheral neuropathy [27], to 28%
hen there was clinical suspicion of CAD and silent MI was
etected by DGE-MRI [25], and to 37% in patients with
eripheral artery disease with silent MI detection by dipyri-
amole thallium scintigraphy [26] (Table 3). The proportion
f silent MI among all MI varied from 29 to 70% depending on
he study, and was particularly high in patients with cardiac
utonomic neuropathy.
ncidence of silent MI in the general population
he incidence of silent MI in studies performed in the gen-
ral population was assessed in nine studies (ﬁve in North
merica, three in Europe and one in Oceania), in which the
uration of follow-up varied from 6 to 34 years (Table 4)
10,13,14,17,28—32]. One of them included very old sub-
ects [17]. The inﬂuence of age on the incidence of silent
I was examined in the Reykjavik [13,14] and Honolulu [31]
ohorts. In all cases, silent MI was detected by ECG (Q wave,
nd ST-T abnormalities in the Atherosclerosis Risk in Com-
unities [ARIC] study [29]).
Results generally showed relatively narrow between-
tudy variations, except for the Bronx AS study in very
ld subjects [17] in which the incidence of silent MI
as around 10 times higher (about 1/4 of these patients
ad a history of angina) (Table 4). In the Reykjavik and
L
u
i
(onolulu cohorts, a direct relationship was found between
ge and the incidence of silent MI [13,14,31]. Comparison of
ata from the Reykjavik male and female cohorts indicated
igher incidence rates in relatively young male subjects than
n their female counterparts [13,14]. Two studies [14,31]
ound an inverted-U relationship between age and the inci-
ence of silent MI in male subjects, but this may have been
ue, at least partly, to a higher mortality rate among old
atients who had experienced a ﬁrst silent MI. However,
n the Reykjavik female cohort, there was an exponential
elationship with age [13]. The ARIC cohort (North America)
29] and the Reykjavik female cohort (Iceland) [13] reported
imilar incidence rates (0.8—0.9/1000 patient-years) for
iddle-aged subjects (∼60 years old). Slightly higher inci-
ence rates (∼1.5/1000 patient-years) were reported in
wo studies (Rochester and Honolulu cohorts) of subjects
ithout obvious risk factors [10,31], while two studies (Rot-
erdam and Multiple Risk Factor Intervention Trial [MRFIT]
ohorts [28,32]) reported higher incidence rates (∼4/1000
atient-years) in populations of subjects at a higher risk for
oronary heart disease or including a proportion of hyper-
ensive patients (Table 4).
ncidence of silent MI in the high-risk
opulation: patients with hypertension or
istory of CAD
our studies conducted in Europe, America and Asia
ncluded hypertensive patients (Table 5) [18,33—35]. The
ldest ones (MRC trial, 1988 [18]; Metoprolol Atheroscle-
osis Prevention in Hypertensives [MAPHY] study, 1991
35]) reported the highest rates of silent MI prevalence
∼5—8/1000 patient-years), while the rates were notably
ower (∼1—2/1000 patient-years) in the more recent ones
Hypertension Optimal Treatment [HOT] study, 1998 [34];
nglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure
owering Arm [ASCOT-BPLA], 2005 [33]). Duration of follow-
p was 3.8—5.5 years.
Two studies carried out in Europe or North America
ncluded patients with a history of cardiovascular disease
angina, MI, revascularization, etc.) (Table 5) [36,37]. These
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Table 4 Incidence of silent MI in the general population.
Cohort name and/or year Region n Sex Mean or
range age
(years)
Method of
diagnosis
Follow-up
duration
(years)
Incidence (per 1000
patient-years)
MRFIT 1987 [32] USA 12 866 M 35—57 at
entry
ECG Q wave 6 4.4
Honolulu 1989 [31] Hawaii 7331 M ∼54 ECG Q wave 6 0.6 at age 50—54,
1.3 at age 60—64,
0.5 at age 65—68
Bronx AS 1990 [17] USA 349 M/F 79 ECG Q wave ≤ 8 24 (72 if history of
MI)
Framingham 1990 [30] USA 5070 M/F 35—94 ECG Q wave 34 M/F 2.7/1.3
Reykjavik 1995 [14] Europe 9141 M 33—60 at
entry
ECG ≤ 20 1.2 at age 50, 3.0 at
age 60, 1.5 at age 75
Reykjavik 1998 [13] Europe 9773 F 32—59 at
entry
ECG ≤ 24 < 0.2 at age < 40,
∼0.8 at age ∼60,
∼2.0 at age 75
ARIC 2002 [29] USA 12 843 M/F 45—65 ECG Q wavea 9 0.9
Rochester 2005 [10] USA 603 M/F 58 ECG ∼17 1.5
Rotterdam 2006 [28] Europe 5148b M/F 68 ECG 6.4 3.8 (M/F 4.2/3.6)
ARIC: atherosclerosis risk in communities; AS: Aging Study; ECG: electrocardiogram; F: female; M: male; MI: myocardial infarction;
MRFIT: multiple risk factor intervention trial.
a And ST-T abnormalities.
b 30% hypertensive.
Table 5 Incidence of silent MI in at-risk patients.
Cohort name and/or year Region n Sex Mean or
range age
(years)
Method of
diagnosis
Follow-up
duration
(years)
Incidence (per
1000
patient-years)
Patients with arterial hypertension
ASCOT-BPLA 2005 [33] Europe 19 257a M/F 63 ECG 5.5 0.6—0.8b M/F
HOT 1998 [34] Europe,
USA,
Asia
18 790 M/F 61.5 ECG 3.8 1.8 (3.3 in
diabetics)
MAPHY 1991 [35] Europe,
Canada
3234 M 40—64 at
entry
ECG Q wave 4.2 4.9—7.2 M/F
MRC trial 1988 [18] Europe 17 354 M/F 35—64 ECG Q wave 5.5 M/F 7.5/8.4b
Patients with a history of cardiovascular disease
HERS 2001 [36] USA 2763c F 67 ECG Q wave 4.1 1.0b
4S 1998 [37] Europe 4444d M/F 59 Not
speciﬁed
5.4 8.3
4S: Scandinavian Simvastatin Survival Study; ASCOT-BPLA: anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm;
CAD: coronary artery disease; ECG: electrocardiogram; F: female; HERS: Heart and Estrogen/progestin Replacement Study; HOT:
Hypertension Optimal Treatment; M: male; MAPHY: metoprolol atherosclerosis prevention in hypertensives; MI: myocardial infarction;
MRC: medical research council.
a 26.7% had diabetes.
b Calculated cumulative incidence per 1000 patients/year.
c Subjects with CAD (history of MI, revascularization, occlusion, etc.); 31.6% had diabetes.
d Patients with a history of MI and hypercholesterolaemia, 80% of men; 4.6% had diabetes.
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Table 6 Incidence of silent MI in subjects with type 2 diabetes.
Cohort name and/or year Region n Sex Mean or
range age
(years)
Method of
diagnosis
Follow-up
duration
(years)
Incidence
(per 1000
patient-
years)
Studies in diabetics mostly without a history of cardiovascular disease or with just risk factors
CARDS 2004 [40] Europe 2838a M/F 62 ECG Q wave 3.9 0.9b
ASCOT DM2 2008 [39] Europe 5127c M/F 63 ECG 5.5 0.8b
FIELD 2010 [38] Australia,
Finland,
New-
Zealand
9795d M/F 62 ECG Q wave 5 5.5b
Studies in diabetics with a history of cardiovascular disease
PROactive 2005 [43] Europe 5238e M/F 62 ECG Q wave
or R-wave
reduction
2.9 2.9b
PROactive 2007 [42] Europe 2445f M/F 62 ECG Q wave
or R-wave
reduction
2.9 3.5b
BARI 2D 2009 [41] North/South
Americas,
Europe
2368g M/F 62 ECG Q wave 5.3 1.8b
ASCOT DM2: Anglo-Scandinavian Cardiac Outcomes Trial Diabetes Mellitus type 2; BARI 2D: Bypass Angioplasty Revascularization Inves-
tigation 2 Diabetes; CAD: coronary artery disease; CARDS: Collaborative Atorvastatin Diabetes Study; ECG: electrocardiogram; F:
female; FIELD: Fenoﬁbrate Intervention and Event Lowering in Diabetes; M: male; MI: myocardial infarction; PROactive: PROspective
pioglitAzone Clinical Trial In macroVascular Events.
a Greater or equal to 1 cardiovascular risk factor.
b Calculated cumulative incidence per 1000 patient-years.
c Either untreated (systolic/diastolic blood pressure ≥ 160/100mmHg) or treated (systolic/diastolic blood pressure≥ 140/90mmHg)
hypertension and≥ 2 other risk factors.
d 21.8% with a history of MI, angina, or revascularization.
e History of a major cardiovascular event (MI, stroke, percutaneous coronary intervention, coronary artery bypass surgery), acute
coronary syndrome, objective CAD, and/or peripheral artery disease.
f Previous MI.
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wo studies reported cumulative incidence rates varying
rom 1.0/1000 patient-years (detection by ECG) in the
eart and Estrogen/progestin Replacement Study (HERS) of
omen with CAD [36] to ∼8/1000 patient-years (detection
ethod not speciﬁed, more frequent clinic visits) in the
candinavian Simvastatin Survival Study (4S) study mainly
f hypercholesterolaemic men with a history of angina or MI
37].
ncidence of silent MI in diabetic patients
he incidence of silent MI in diabetic patients was assessed
n six studies carried out during recent years for the evalua-
ion of the clinical effects of antidiabetic agents in Europe,
orth and South America, and Australia and New Zealand
Table 6). Three studies were performed in patients mainly
ithout a history of cardiovascular disease (primary preven-
ive therapy) [38—40] and three studies in patients with a
istory of angina or macrovascular disease (secondary pre-
entive therapy) [41—43]. In all of these studies, diabetic
atients had associated risk factors (hypertension, hyperlip-
daemia, proteinuria, retinopathy, smoking, family history,
w
i
f
o
6py.
tc.). The duration of the follow-up was approximately
—5.5 years, depending on the study. Silent MI was detected
y ECG (or R-wave reduction in one study).
The incidence of silent MI was relatively low
0.8—0.9/1000 patient-years) in diabetic patients with
isk factors but free of any major cardiac event (ASCOT
ype 2 diabetes mellitus [DM2] [39] and Collaborative
torvastatin Diabetes Study [CARDS] [40] studies), inter-
ediate (1.8/1000 patient-years) in diabetic patients with
history of angina treated by revascularization or medical
herapy (BARI 2D study [41]), and highest (2.9—5.5/1000
atient-years) in studies that included only or partly (22%)
iabetic patients with a history of MI (PROspective piogli-
Azone Clinical Trial In macroVascular Events [PROactive]
42,43] and Fenoﬁbrate Intervention and Event Lowering in
iabetes [FIELD] [38] studies, respectively). In the FIELD
tudy [38], a silent MI occurred in 166 of the 7640 patients
ithout a history of cardiovascular disease (mean estimated
ncidence of 4/1000 patient-years), and silent MI accounted
or 38.3% of the ﬁrst cases of MI (245 silent MIs of a total
f 640 ﬁrst MIs), whereas after a ﬁrst MI (clinical or silent),
4.5% were silent [38].
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Table 7 Risk factors for clinical MI and silent MI in diabetic patients in the FIELD study [38].
Clinical MI Silent MI Probability for
heterogeneity
OR (95% CI) P OR (95% CI) P
Male gender 1.38 (1.07—1.78) 0.01 1.15 (0.85—1.57) 0.37 0.37
Age 1.03 (1.02—1.05) < 0.001 1.03 (1.01—1.05) 0.008 0.60
Diabetes duration 0.99 (0.98—1.01) 0.48 0.97 (0.95—0.99) 0.02 0.12
Prior cardiovascular disease 2.12 (1.71—2.64) < 0.001 1.62 (1.22—2.17) < 0.001 0.14
Diabetic neuropathy 1.34 (1.04—1.73) 0.02 1.07 (0.75—1.52) 0.72 0.30
HbA1c 1.14 (1.06—1.23) < 0.001 1.04 (0.94—1.16) 0.41 0.17
Creatinine 1.01 (1.00—1.02) 0.009 1.00 (0.99—1.01) 0.55 0.25
Microalbuminuria 1.42 (1.12—1.80) 0.003 1.35 (1.00—1.83) 0.05 0.79
Macroalbuminuria 2.21 (1.53—3.20) < 0.001 2.51 (1.56—4.03) < 0.001 0.68
Insulin use 1.42 (1.08—1.88) 0.01 1.05 (0.70—1.59) 0.80 0.23
CI: conﬁdence interval; FIELD: fenoﬁbrate intervention and event lowering in diabetes; HbA1c: haemoglobin A1c; MI: myocardial
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Predictive factors of silent MI
Some studies assessed the risk factors for the occurrence
of silent MI in subjects from the general population (six
studies), in patients with a history of cardiovascular disease
(three studies), or in diabetic patients (two studies). The
most frequently reported risk factor for silent MI is hyper-
tension, which was reported in all six studies in the general
population and in one of the two studies in diabetic patients,
but in none of the three studies in patients with a history of
cardiovascular disease. Impaired glucose tolerance or dia-
betes was quoted as a risk factor in three of the six studies
in the general population and in two of the three studies in
patients with cardiovascular disease.
The recent FIELD study [38] evaluated the odds ratios
(ORs) of different potential risk factors for clinical MI
and silent MI in diabetic patients (Table 7). Among the
nine factors that were found to be signiﬁcantly predictive
of clinical MI, three were also found to be signiﬁcantly
predictive of silent MI (age, prior cardiovascular disease,
micro/macroalbuminuria), along with diabetes duration.
Moreover, there was no signiﬁcant difference between the
ORs for clinical MI and silent MI for any potential risk factor
tested, indicating similar risks for clinical MI and silent MI
whatever the potential risk factor considered.
Silent MI and prognosis
Regarding the prognosis in silent MI, four studies in the
general population found that the presence of silent MI
increased the risk of all-cause mortality by a factor of
1.8—3.6, and the risk of cardiovascular mortality or a
major ischaemic event by a factor of 1.9—3.2 [12,14,16,17].
Similarly, in three studies of patients with pre-existing car-
diovascular disease, silent MI increased the risk of all-cause
mortality by a factor of 1.9—3.4 and that of a major car-
diac event by 2.2—8.3 [20,21,23]. As for diabetic patients,
three studies reported increases in all-cause mortality by
a factor of 1.1—5.0 and in cardiac mortality or a major
cardiac event by 1.8—7.3 [24,25,38]. On the whole, in all
h
y
s
o
itudies (of patients with or without risk factors, a history
f cardiovascular disease or diabetes), there was no major
ifference between silent MI and clinical MI as to the risk
or mortality or a major cardiac event. Typically, the FIELD
tudy reported very similar cumulative incidences of cardio-
ascular disease over 2 years of follow-up between diabetic
atients with silent or clinical MI receiving placebo (hazard
atios of 4.55 and 4.51, respectively), while all-cause mor-
ality rates were 13.8% and 15.2%, respectively, in the two
atient groups [38].
iscussion
he present review of publications that reported data on
ilent MI detection indicates different prevalence rates
epending on the patient population considered. In the
ohorts that provided data from non-diabetic patients
ithout known cardiovascular disease, the prevalence of
ilent MI was 0.3—5.4% (6.4% in very old subjects). Such
arge between-study variations are indicative of some
eterogeneity between the studies in terms of the sub-
ects’/patients’ characteristics (e.g. sex, age, proportion of
iabetic patients) and/or the method of silent MI detection.
n diabetic patients without CAD, the prevalence of silent MI
as about 4%, but it was found to rise to 10% in patients with
eripheral neuropathy and up to about 30% in the presence
f established coronary or peripheral artery disease.
In the studies of non-diabetic subjects, the incidence
f silent MI showed large variations: it was 1—1.5/1000
erson-years in healthy subjects free from risk factors aged
60 years, 1—5/1000 patient-years in patients with cardio-
ascular risk factors (e.g. hypertension, hyperlipidaemia)
r elderly patients, up to ∼8/1000 patient-years in the 4S
tudy of mainly male patients with a history of CAD and
ypercholesterolaemia, and much higher (24/1000 patient-
ears) in the Bronx AS cohort, which included very old
ubjects. In the studies of diabetic patients, the incidence
f silent MI was about 1/1000 patient-years in two stud-
es of patients without a history of cardiovascular disease,
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—3.5/1000 patient-years in three studies of patients with
ngina or a history of macrovascular disease and highest
4/1000 patient-years) in patients without a history of car-
iovascular disease of the FIELD study.
The literature search for data on the prevalence and inci-
ence of silent MI in patients with hypertension retrieved
inimal information. Two cohorts of hypertensive patients
ithout a history of cardiac disease suggested some
elationship between diastolic blood pressure and the preva-
ence of silent MI (prevalence of ∼1.4% in hypertensive
atients with diastolic blood pressure 90—109mmHg (MRC
rial) versus 2.8% in patients with diastolic blood pres-
ure 100—125mmHg) (IPPPSH-Italy) [18,19]. Interestingly,
egarding the incidence of silent MI, four large studies
n hypertensive patients reported an inverse relationship
etween the incidence rate of silent MI and the date of
tudy completion: 5—8/1000 patient-years in two studies
MRC trial [18], MAPHY study [35]) published in 1988 and
991, and 1.8 and < 1/1000 patient-years in two studies (HOT
34] and ASCOT-BPLA studies [33]) published in 1998 and
005, respectively. This observation might reﬂect gradual
mprovements over time in the medical management of
atients at risk for cardiovascular disease.
Different factors should be considered when interpret-
ng the ﬁndings reported herein, including the region where
he studies were conducted, the method used for the detec-
ion of silent MI, and the date of completion of the studies.
atients are more aware nowadays about signs and symp-
oms of MI, and hence are more likely to seek prompt
edical assistance. Also, enhanced diagnostic capabilities
ver the years may have resulted in lower proportions of
nrecognized MIs in the more recent studies [29]. Caution is
arranted when comparing data from studies that were con-
ucted in different regions in the world, given the diversity
f the populations and pathologies in which the prevalence
nd incidence of silent MI were assessed. However, the
esults do not reveal any major differences between Europe
essentially Northern countries) and other regions of the
orld, and there is relative between-region homogeneity of
ata for patient populations and pathologies with compara-
le characteristics (age, presence or absence of diabetes,
nd/or history of cardiovascular diseases).
The intrinsic value of the reported data on the prevalence
nd incidence of silent MI should be examined in relation
o the detection method that was used in the studies. The
pparent large increase in the prevalence of silent MI among
atients with a history of cardiovascular disease may have
een inﬂuenced notably by the detection method used. In
ost studies of patients with a history of cardiovascular dis-
ase (two of three studies of diabetic patients and all four
tudies of non-diabetic patients), it is notable that silent
I was detected by stress scintigraphy or echography or by
GE-MRI, unlike all of the studies of patients free of known
ardiovascular disease, in which silent MI was detected by
outine ECG. However, ECG may have low sensitivity, as
ilent MI ECG ﬁndings may not persist in the long term due to
egression of Q waves with time [31]. Also, infarction size
reatly inﬂuences its detectability by ECG [44], so that a
elatively large proportion of small silent MIs are not associ-
ted with characteristic Qwaves (‘‘non-Q-wave’’ silent MIs),
hile they can be revealed by cardiac MRI [20]. Finally, stress
chocardiography may detect silent myocardial ischaemiaP. Valensi et al.
hat may be reversible at rest, and in this case not reﬂective
f silent MI.
In common clinical practice, it is clear that only ECG,
espite its imperfections, can be used routinely for the
xamination of patients at high risk of MI, but who are
ree from symptoms. Biological markers such as troponin
re unhelpful here, and MI should thus be conﬁrmed, for
nstance by echocardiography, which is considered the most
seful non-invasive test in the assessment of Q waves despite
ts rather low sensitivity, especially for small MIs.
onclusions
imilarly to silent myocardial ischaemia, silent MI involves
high proportion of patients with risk factors such as
ypertension, a history of cardiovascular disorders, and dia-
etes. The fact that the prevalence of silent MI increases
arkedly with increasing age and with a history of cardio-
ascular disease (coronary or peripheral artery disease), and
hat its prognosis is considered close to that of clinical MI
9,14,16,17], amply justify its systematic early detection
nd active management in at-risk patients.
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